IMMIX BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
IMMIX BIOPHARMA, INC. (IMMX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.67 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.55M shares, a 76.74% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 114.00K shares, a 356.00% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 85.44K shares, a 55.35% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 406.00K shares, a 3590.91% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.39M shares, a 11.31% decline from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.57M shares, a 111.69% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 742.67K shares, a 25.61% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 591.25K shares, a 42.54% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.55M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 1.67M shares 10-Q · filed 2026-08-07 | 1.75M shares derived: sum of 3 quarters · filed 2026-08-07 | 2.16M shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 114.00K shares 10-Q · filed 2026-05-07 | 199.44K shares derived: sum of 2 quarters · filed 2026-05-07 | 605.44K shares derived: sum of 3 quarters · filed 2026-05-07 | 1.48M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 85.44K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 491.44K shares derived: sum of 2 quarters · filed 2026-03-27 | 1.37M shares derived: sum of 3 quarters · filed 2026-03-27 | 1.39M shares 10-K/A · filed 2026-03-27 |
| 2025-09-30 | 406.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 1.28M shares derived: sum of 2 quarters · filed 2025-11-07 | 1.31M shares 10-Q · filed 2025-11-07 | 1.36M shares derived: sum of 4 quarters · filed 2026-03-27 |
| 2025-06-30 | 878.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | 903.00K shares 10-Q · filed 2025-08-08 | 958.00K shares derived: sum of 3 quarters · filed 2026-03-27 | 969.00K shares derived: sum of 4 quarters · filed 2026-03-27 |
| 2025-03-31 | 25.00K shares 10-Q · filed 2025-05-08 | 80.00K shares derived: sum of 2 quarters · filed 2026-03-27 | 91.00K shares derived: sum of 3 quarters · filed 2026-03-27 | |
| 2024-12-31 | 55.00K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | 66.00K shares derived: sum of 2 quarters · filed 2026-03-27 | 1.57M shares 10-K/A · filed 2026-03-27 | |
| 2024-09-30 | 11.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.52M shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 1.51M shares 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 742.67K shares 10-K · filed 2025-03-25 | ||
| 2023-09-30 | 742.67K shares 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 580.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 580.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 591.25K shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 580.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 580.00K shares derived: sum of 2 quarters · filed 2022-11-09 | 591.25K shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 11.25K shares 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | 11.25K shares 10-Q · filed 2022-05-13 | |||
| 2021-12-31 | 1.03M shares 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |